Cargando…

COVID-19 Vaccination after Allogeneic Stem Cell Transplantation: Real Word Data on Safety and Efficacy. a Single Center Experience.

Introduction Different vaccines have been recently approved by FDA and EMA for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, demonstrating a protection rate ranging from 60% to almost 95% in phase II/III trials. Immunocompromised patients, including those...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neagoie, Adela, Sommer, Charlotte, Gantner, Andrea, Wais, Verena, Schnell, Jacqueline, Simon, Hannah, Viardot, Andreas, Döhner, Hartmut, Bunjes, Donald, Sala, Elisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. Published by Elsevier Inc. 2021
Materias:	722.Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701595/ http://dx.doi.org/10.1182/blood-2021-151061

Ejemplares similares

Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients
por: Minehart, Janna C., et al.
Publicado: (2021)

Antibody Response to Sars-Cov-2 Vaccination in Patients Following Allogeneic Hematopoietic Cell Transplantation
por: Cicin-Sain, Caroline, et al.
Publicado: (2021)

Antibody Response to 2-Dose Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients
por: Maillard, Alexis, et al.
Publicado: (2021)

Response to BNT162b2 Sars-Cov-2 Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
por: Saraceni, Francesco, et al.
Publicado: (2021)

Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine
por: Clemenceau, Beatrice, et al.
Publicado: (2021)

Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients
por: Le Bourgeois, Amandine, et al.
Publicado: (2021)

Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients
por: Harrington, Patrick, et al.
Publicado: (2021)

Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Jullien, Maxime, et al.
Publicado: (2021)

Chronic Graft-Versus-Host Disease (cGVHD) Exacerbation after Sars-Cov-2 Covid Vaccination
por: Trunk, Andrew D., et al.
Publicado: (2021)

Humoral and T Cell Immune Responses to Sars-Cov-2 Vaccination in Hematopoietic Cell Transplant Recipients
por: Gavriilaki, Eleni, et al.
Publicado: (2021)

Serological Response Following BNT162b2 Anti-Sars-Cov-2 mRNA Vaccination in Hematopoietic Stem Cell Transplantation Patients
por: Attolico, Imma, et al.
Publicado: (2021)

Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2021)

Timing and Immune Status after Cellular Therapies Predict Response to COVID-19 Vaccines
por: Tamari, Roni, et al.
Publicado: (2021)

Identification of Respiratory Viral Infection in Hematopoietic Stem Cell Transplant Recipients - Impact on Non Relapse Mortality
por: Imlay-Gillespie, Louise, et al.
Publicado: (2015)

Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation
por: Hütter-Krönke, Marie Luise, et al.
Publicado: (2023)

Allogeneic natural killer cell therapy
por: Berrien-Elliott, Melissa M., et al.
Publicado: (2023)

Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells
por: Qasim, Waseem
Publicado: (2023)

Allogeneic and Autologous Hematopoietic Transplants Can be Safely Performed after COVID-19 Infections
por: Ramdial, Jeremy L., et al.
Publicado: (2021)

Efficacy of a Third Sars-Cov-2 Vaccine Dose in Allogeneic Hemopoietic Cell Recipients: a Systematic Review and Meta-Analysis
por: Rubin, Micah, et al.
Publicado: (2023)

Sars-Cov-2 Infection and Vaccination in Recipients of Reduced-Intensity Conditioning, Posttransplantation Cyclophosphamide (PTCy)-Based Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Dimitrova, Dimana, et al.
Publicado: (2022)

Risk Factors Influencing Humoral Response to COVID 19 Vaccination after Allogeneic Stem Cell Transplantation
por: Hütter-Krönke, Marie Luise, et al.
Publicado: (2022)

Risk Factors for Severe Form of COVID-19 after Allogeneic Hematopoietic Stem Cell Transplantation: A SFGM-TC Multicentre Cohort Study
por: Xhaard, Alienor, et al.
Publicado: (2020)

Putative Protective Role of Sars-Cov-2-Specific T Cells in an HCT Patient Transplanted during Active COVID19 Infection
por: Pourhassan, Hoda, et al.
Publicado: (2022)

Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies
por: Cichocki, Frank, et al.
Publicado: (2023)

Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies
por: Quach, David H., et al.
Publicado: (2023)

COVID-19 in Pediatric Hematopoietic Cell Transplant Recipients: A CIBMTR Study
por: Bhatt, Neel S., et al.
Publicado: (2021)

COVID-19 in Children Following Hematopoietic Cell Transplantation: A Multinational Study of the European Bone Marrow Transplantation Society (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH)
por: Averbuch, Diana, et al.
Publicado: (2021)

COVID-19 Infection of HSCT Recipients Is Associated with High Mortality but No Detectable Cytokine Storm at Presentation
por: Lucchini, Giovanna, et al.
Publicado: (2021)

COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)
por: Ljungman, Per, et al.
Publicado: (2020)

Clinical Characteristics and Outcomes of COVID-19 in HSCT Recipients
por: Machado, Clarisse MARTINS, et al.
Publicado: (2020)

Sarcopenia Screening Allows Identifying High-Risk Patients for Allogenic Stem Cell Transplantation
por: Kirsten, Johannes, et al.
Publicado: (2021)

An Unusual Presentation of Nocardiosis in an Allogeneic Transplant Recipient
por: Ibrahim, Uroosa, et al.
Publicado: (2016)

Treatment of allosensitized patients receiving allogeneic transplantation
por: Ciurea, Stefan O., et al.
Publicado: (2021)

Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients
por: Greiner, Jochen, et al.
Publicado: (2019)

Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis
por: Gooptu, Mahasweta, et al.
Publicado: (2022)

Type 1 interferon to prevent leukemia relapse after allogeneic transplantation
por: Magenau, John M., et al.
Publicado: (2021)

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution
por: Maurer, Katie, et al.
Publicado: (2021)

Assessment of Serology after Sars-Cov-2 Vaccine in Allogeneic HCT Recipients
por: Baker, Melissa, et al.
Publicado: (2021)

Genetic associations with immune-mediated outcomes after allogeneic hematopoietic cell transplantation
por: Martin, Paul J., et al.
Publicado: (2022)

EASIX-1year and late mortality after allogeneic stem cell transplantation
por: Kordelas, Lambros, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lt3u449239pmm8j5rhtnii4npm